,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gjcb ,,in ,,the ,,house ,,of ,,representatives ,march #i1 #bjbb ,ms4 ,kuster introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77 with respect to a process to inform persons submitting an abbreviated application for a new drug whether the new drug is qualitatively or quantitatively the same as a listed drug1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,increasing ,transparency in ,generic ,drug ,applications ,act of #bjbb4 #b4 ,determining whether proposed new generic drugs are qualitatively or quantitatively the same as the listed drug 7a7 ,in general ,section #eje7;j77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77#c77 is amended by adding at the end the following3 7,h7 7i7 ,upon request 7in controlled correspondence or otherwise7 by a person that has submitted or intends to submit an abbreviated application for a new drug under this subsection or on the ,secretary's own initiative during the review of such abbreviated application1 the ,secretary shall inform the person whether such new drug is qualitatively and quantitatively the same as the listed drug4 7ii7 ,if the ,secretary determines that such new drug is not qualitatively or quantitatively the same as the listed drug1 the ,secretary shall identify and disclose to the person-- 7,i7 the ingredient or ingredients that cause the new drug not to be qualitatively or quantitatively the same as the listed drug2 and 7,,ii7 the quantity or proportion of any ingredient in the listed drug for which there is an identified quantitative deviation4 7iii7 ,if the ,secretary determines that such new drug is qualitatively and quantitatively the same as the listed drug1 the ,secretary shall not change or rescind such determination after the submission of an abbreviated application for such new drug under this subsection unless-- 7,i7 the formulation of the listed drug has been changed and the ,secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness2 or 7,,ii7 the ,secretary makes a written determination that the prior determination must be changed because an error has been identified4 7iv7 ,if the ,secretary makes a written determination described in clause 7iii77,,ii71 the ,secretary shall provide notice and a copy of the written determination to the person making the request under clause 7i74 7v7 ,the disclosures required by this subparagraph are disclosures authorized by law under section #aije of title #ah1 ,united ,states ,code4 4 7b7 ,guidance 7#a7 ,in general ,not later than one year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall issue guidance describing how the ,secretary will determine whether a new drug is qualitatively and quantitatively the same as the listed drug 7as such terms are used in section #eje7;j77#c77;,h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a771 including with respect to assessing p,h adjusters4 7#b7 ,process ,in issuing guidance as required by paragraph 7#a71 the ,secretary of ,health and ,human ,services shall-- 7,a7 publish draft guidance2 7,b7 provide a period of at least #fj days for comment on the draft guidance2 and 7,c7 after considering any comments received1 publish final guidance4 7c7 ,applicability ,section #eje7;j77#c77;,h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 applies beginning on the date of enactment of this ,act1 irrespective of the date on which the guidance required by subsection 7b7 is finalized4